Skip to main content

Table 1 Summary of regimens used for pre- or postoperative chemotherapy in premenopausal women with early-stage breast cancer (n = 50)

From: SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study

Regimen

Patients n (%)

Cycles

Interval (weeks)

Dose per cycle

Cyclophosphamide

Anthracycline

Docetaxel

TAC

23 (46 %)

6

3

500 mg/m2

50 mg/m2 (A)

75 mg/m2

FEC

15 (30 %)

6

3

500 mg/m2

90 mg/m2 (E)

TC

8 (16 %)

6

3

600 mg/m2

75 mg/m2

EC

2 (4 %)

6

3

600 mg/m2

90 mg/m2 (E)

FAC

1 (2 %)

6

3

500 mg/m2

50 mg/m2 (A)

AC

1 (2 %)

6

3

600 mg/m2

60 mg/m2 (A)

  1. T Taxotere® (docetaxel), A adriamycin (doxorubicin), C cyclophosphamide, F fluorouracil, E epirubicin